Although there are no other reports suggesting any beneficial effect of CYP2D6 polymorphisms in relation to breast cancer outcomes, there is much inconsistency in the supposed detrimental effects of the variant alleles with regards to the risk of recurrence. The gene discussed is CYP2D6; the disease is breast carcinoma.